(+)-epicatechin

AssetAlso called Epicatechin, Evesse EPC, +Epi

Flavanol that improves endothelial and vasodilatory function

Stage
Phase 2, no development reported
Modality
Supplement
Target
Not known
3
Indications
10
Trials
2
Developers

No development reported since March 2022. Last activity: Trial NCT04386304 completed. clinicaltrials.gov

Indications

3

In the full profile

  • Owner and partners2
  • Trials10
  • Evidence for its targets1
  • Competitors2
  • Aging relevance4
  • Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets